Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Dominica Health Times.
Press releases published on April 29, 2025
Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2025
GlobeNewswire
·
April 29, 2025
BANNOCKBURN, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results …
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
GlobeNewswire
·
April 29, 2025
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference …
Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
GlobeNewswire
·
April 29, 2025
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first …
EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy
GlobeNewswire
·
April 29, 2025
Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical trial for patients with relapse or refractory multiple …
Ostarine Mk-2866 SARMs: Ostarine Cycle, Osta 2866 Benefits, Ostarine PCT, Ostarine Mk-2866 Dosage, Osta 2866 Side Effects, What Is Ostarine, Buy, Before and After By CrazyBulk
GlobeNewswire
·
April 29, 2025
New York , April 29, 2025 (GLOBE NEWSWIRE) -- NEW YORK, April 28, 2025: Crazy Bulk OSTA 2866: A Safe Alternative to Ostarine MK 2866 Crazy Bulk OSTA 2866 is a safe and legal substitute for Ostarine MK 2866. We now have a new type of bodybuilding …
Regeneron Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
April 29, 2025
First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22 First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 billion versus first quarter 2024 First quarter 2025 EYLEA …
Prime Biome Safety Report 2025: Exposing Review Scams, Customer Complaints & Safe Buying Options
GlobeNewswire
·
April 29, 2025
St. Petersburg, Florida, April 29, 2025 (GLOBE NEWSWIRE) -- PrimeBiome is kind of blowing up right now (Rating: 4.97/5), and for good reason. People are raving about smoother digestion, way less bloating, and that glow-up skin vibe. It's a smart, science- …
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
GlobeNewswire
·
April 29, 2025
Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries BROOMFIELD, Colo., …
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire
·
April 29, 2025
LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on …
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
GlobeNewswire
·
April 29, 2025
- ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure - - Approval based on the pivotal Phase 3 VIITAL™ study, showing ZEVASKYN resulted in significant wound healing and pain reduction after a …
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
GlobeNewswire
·
April 29, 2025
HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief …
ProDentim Reviews (ALERT): I TRIED IT, Tracked It, and Exposed the Good, Bad & Unexpected
GlobeNewswire
·
April 29, 2025
Tallmadge, Ohio, April 29, 2025 (GLOBE NEWSWIRE) -- ProDentim is rated 5 stars by over 95,000 satisfied customers. It combines 3.5 billion CFUs of powerful probiotics, including Lactobacillus Paracasei, B.lactis BL-04®, and Lactobacillus Reuteri, along …
Britisches Unternehmen Stablepharma Ltd. beginnt mit klinischen Studien der Phase I für den weltweit ersten ohne Kühlung auskommenden Tetanus- und Diphtherie-Impfstoff
GlobeNewswire
·
April 29, 2025
LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Nach der MHRA-Zulassung hat Stablepharma Ltd eine klinische Studie der Phase I mit seinem Hauptkandidaten, dem kühlschrankfreien Tetanus- und Diphtherieimpfstoff SPVX02, begonnen. Die klinische Phase-I-Studie am …
L’entreprise de biotechnologie britannique Stablepharma Ltd. lance en première mondiale un essai de Phase I ciblé sur un vaccin thermostable contre le tétanos et la diphtérie
GlobeNewswire
·
April 29, 2025
LONDRES, 29 avr. 2025 (GLOBE NEWSWIRE) -- Après avoir obtenu l’autorisation de la MHRA, l’autorité britannique de réglementation du marché des dispositifs médicaux, Stablepharma Ltd. entre en essai clinique de Phase I pour son principal candidat, SPVX02, …
Microbiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma
GlobeNewswire
·
April 29, 2025
CAMBRIDGE, United Kingdom, April 29, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism …
DEBRA Research Announces Impact Investment into Nova Anchora to Advance Protein Therapy for Epidermolysis Bullosa
GlobeNewswire
·
April 29, 2025
Additional investors include global investment firm Viking Global Investors, charity foundation CureEB, the Epidermolysis Bullosa Medical Research Foundation (EBMRF), and Stanford University. The financing will enable Nova Anchora to advance its lead …
Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung
GlobeNewswire
·
April 29, 2025
Pratteln, Schweiz, 29. April 2025 - Santhera Pharmaceuticals (SIX: SANN) hat heute die Einladung zur ordentlichen Generalversammlung (GV) veröffentlicht, die am 20. Mai 2025 um 10:00 Uhr MESZ im Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Schweiz, …
Santhera Publishes Agenda for its Annual General Meeting
GlobeNewswire
·
April 29, 2025
Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 20, 2025, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, …
Lumineye Introduces Sublingual Nano-Drop Formula to Help Support Normal Eye Comfort and Clarity
GlobeNewswire
·
April 29, 2025
Sheridan, Wyoming, USA, April 29, 2025 (GLOBE NEWSWIRE) -- Lumineye, a pioneering company in the health and wellness sector, today announced the launch of its new product: The Lumineye Nanodrop. This advanced dietary supplement utilizes a novel sublingual …